Current management of patients with nonalcoholic fatty liver disease

Elsheikh, Elzafir; Henry, Linda; Younossi, Zobair M.

doi:10.1586/17446651.2013.846212

Cited by 4 publications

(8 citation statements)

References 104 publications

(113 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13,23 In addition, a radiological assessment may identify fats through increased echogenicity on ultrasonography, hypodense fat on non-contrast computed tomography and fat content on magnetic resonance imaging. 23 …”

Section: Mechanisms Of Diabetes-induced Liver Damagementioning

confidence: 99%

“…53 For patients with NAFLD and NASH, no specific treatments yet exist apart from diet and lifestyle modifications to reduce body weight and prevent further injury. 23,54 However, combined pharmacological therapy is recommended to improve insulin sensitivity in the liver (metformin and pioglitazone) and its periphery (thiazolidinediones), together with other drugs such as betaine, atorvastatin, losartan and orlistate. 7,13,53 However, the clinical value of these treatments are very subjective.…”

Section: Mitogen-activated Protein Kinasementioning

confidence: 99%

See 1 more Smart Citation

Mechanisms of Diabetes-Induced Liver Damage: The role of oxidative stress and inflammation

Mohamed¹,

Nafizah²,

Zariyantey³

et al. 2016

SQUMJ

351

199

View full text Add to dashboard Cite

Diabetes mellitus is a non-communicable disease that occurs in both developed and developing countries. This metabolic disease affects all systems in the body, including the liver. Hyperglycaemia, mainly caused by insulin resistance, affects the metabolism of lipids, carbohydrates and proteins and can lead to nonalcoholic fatty liver disease, which can further progress to non-alcoholic steatohepatitis, cirrhosis and, finally, hepatocellular carcinomas. The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response; this activates the transcription of pro-apoptotic genes and damages hepatocytes. Significant involvement of pro-inflammatory cytokinesincluding interleukin (IL)-1β, IL-6 and tumour necrosis factor-α-exacerbates the accumulation of oxidative damage products in the liver, such as malondialdehyde, fluorescent pigments and conjugated dienes. This review summarises the biochemical, histological and macromolecular changes that contribute to oxidative liver damage among diabetic individuals.

show abstract

Section: Mechanisms Of Diabetes-induced Liver Damagementioning

confidence: 99%

Section: Mitogen-activated Protein Kinasementioning

confidence: 99%

Mechanisms of Diabetes-Induced Liver Damage: The role of oxidative stress and inflammation

Mohamed¹,

Nafizah²,

Zariyantey³

et al. 2016

SQUMJ

351

199

View full text Add to dashboard Cite

show abstract

“…For patients with DM, no safe treatments yet exist apart from diet and lifestyle modifications ⦋14⦌. (Elsheikh et al, 2013). However, combined pharmacological therapy is recommended to improve insulin sensitivity in the liver (metformin and pioglitazone) and its periphery (thiazolidinediones), together with other drugs such as betaine, atorvastatin, losartan and orlistate ⦋15⦌.…”

Section: Discussionmentioning

confidence: 99%

Effect of administration of Ehretia anacua aqueous extract on blood glucose level in alloxan - induced diabetic rat

Abimbola¹,

Ademola²,

Olawande³

2021

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

The effects of crude aqueous extract of Ehretia anacua on alloxan induced diabetic rats was investigated. Male albino rats of weighing between 120 to 150 were used, divided into 6 groups of five animals per group. Group I received distilled water throughout of the experiment and served as the control. Group II received 110 mg/kg of alloxan interperitoneally. Groups III, IV, V and VI received 110 mg/kg of alloxan and in addition administered with aqueous Ehretia anacua extract daily for 14 days. Blood glucose level was monitored at five days interval for fourteen days. Target organs (pancrease) was taken from each rat. The histopathological studies of the pancrease were examined. In alloxan - induced diabetic rats, blood glucose level was significantly increased compared with the control rats. Treating diabetic rats with 50, 100 and 200 mg/kg bw Ehretia anacua caused a significant decrease in the blood glucose level. The Photomicrograph of the histopathology examination of the pancrease (× 100) of the groups treated with alloxan showed poor architecture was destroyed whereas those treated with Ehretia nancua showed normal architecture. This illustrates the amelliorative effects of the extract on the alloxan-induced tocicity. It could be concluded from these results that, Ehretia nancua extract should be used in manufacture processes of the natural products as functional foods or as a dietary supplement with anti-diabecretic activity as hypoglycemic effect.

show abstract

“…This hepatocyte ballooning involves an enlargement of hepatocytes and their clarification. Additionally, NASH includes lobular inflammation, which consists of the infiltration of lymphocytes, macrophages, and neutrophils, as well as focal hepatocyte necrosis [ 11 , 12 ]. NASH may evolve into liver cirrhosis and/or progress to end-stage liver disease and hepatocellular carcinoma [ 10 ].…”

Section: Histological Spectrum and Diagnosis Of Nafldmentioning

confidence: 99%

“…The incidence and prevalence of NAFLD, although difficult to accurately estimate due to variations in diagnosis methods [ 5 , 12 ], have significantly increased since the twentieth century and are expected to rise over the coming years both in Western and in developing countries. Although there is a lack of data regarding the incidence of NAFLD [ 3 , 7 , 15 ], the prevalence of the disease, estimated from ultrasound imaging diagnosis, is variable across continents, countries and regions: in Europe, the average prevalence is 25.1% (range, 20.55 to 30.28%, depending on the country); in the USA, the prevalence is estimated at 31% with variations according to ethnicity, as it is higher in Hispanic Americans and lower in European and African Americans; in Latin America, the prevalence of NAFLD is estimated at 44.4% with variations according to countries.…”

Section: Incidence Prevalence and Risk Factors For Nafldmentioning

confidence: 99%

Natural compounds proposed for the management of non-alcoholic fatty liver disease

Merenda,

Juszczak,

Ferier

et al. 2024

Nat. Prod. Bioprospect.

View full text Add to dashboard Cite

Although non-alcoholic fatty liver disease (NAFLD) presents as an intricate condition characterized by a growing prevalence, the often-recommended lifestyle interventions mostly lack high-level evidence of efficacy and there are currently no effective drugs proposed for this indication. The present review delves into NAFLD pathology, its diverse underlying physiopathological mechanisms and the available in vitro, in vivo, and clinical evidence regarding the use of natural compounds for its management, through three pivotal targets (oxidative stress, cellular inflammation, and insulin resistance). The promising perspectives that natural compounds offer for NAFLD management underscore the need for additional clinical and lifestyle intervention trials. Encouraging further research will contribute to establishing more robust evidence and practical recommendations tailored to patients with varying NAFLD grades. Graphical Abstract

show abstract

Current management of patients with nonalcoholic fatty liver disease

Cited by 4 publications

References 104 publications

Mechanisms of Diabetes-Induced Liver Damage: The role of oxidative stress and inflammation

Mechanisms of Diabetes-Induced Liver Damage: The role of oxidative stress and inflammation

Effect of administration of Ehretia anacua aqueous extract on blood glucose level in alloxan - induced diabetic rat

Natural compounds proposed for the management of non-alcoholic fatty liver disease

Contact Info

Product

Resources

About